NHNiklas Hammar

Niklas Hammar

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Niklas Hammar has a total of 129 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Yrke och hjärtinfarkt : en beskrivning grundad på befolkningen i fem län

    by Lars Alfredsson, Niklas Hammar

    Uppskattning av den relativa risen att insjukna i hjärtinfarkt för olika yrkesgrupper. Rapporten är ett uppdrag från Arbetsmiljökommissionen.

  • Open Access

    Association Between Low Serum Iron and Transferrin Saturation and Incident Heart Failure: A Population-Based Cohort Study

    by Carin Corovic Cabrera, Karin Leander, Max Vikström, Martin Jonsson, Niklas Hammar, Mattias Ekström, Patrik Lyngå, Per Tornvall

  • Open Access

    Associations Between Routinely Measured Biomarkers and Pancreatic Cancer Risk in Individuals with Type 2 Diabetes Pre- and Post-Diagnosis

    by Ziying Zhang, Sofia Carlsson, Niklas Hammar, Pilar Acedo, Beth Russell, Shahram Kordasti, Debashis Sarker, Mieke Van Hemelrijck, Aida Santaolalla

    Background/Objectives: Individuals with type 2 diabetes have an increased risk of pancreatic cancer (PC), yet early detection markers remain limited. We examined associations between routinely measured serum biomarkers and subsequent PC risk in this population. Methods: Using the Swedish AMORIS cohort, 101,051 individuals aged ≥50 years at diabetes diagnosis with newly diagnosed type 2 diabetes (1969–2019) were analysed. Ten biomarkers, including liver enzymes, inflammatory markers, renal function, and lipid profiles, were assessed. The primary analysis focused on measurements within ±1 year of the diabetes diagnosis (n = 13,190; Cohort 1). Sensitivity analyses considered broader windows: −3, −5, and −10 years before diagnosis to +1 year after, and from the diagnosis to the end of the follow-up (Cohorts 2–5). Multivariable Cox models adjusted for age and sex were applied. Results: During a mean follow-up of 15.9 years, 192 individuals developed PC. In primary analysis, higher alkaline phosphatase was associated with increased PC risk (HR: 1.16, 95% CI: 1.09–1.24 per 1 SD increase). Higher creatinine was associated with reduced PC risk (HR: 0.55, 95% CI: 0.36–0.83 per 1 SD increase), while haptoglobin (HR: 1.20, 95% CI: 0.97–1.49 per 1 SD increase) suggested a modest positive association. Patterns were consistent across sensitivity analyses. Conclusions: In individuals ≥ 50 years with newly diagnosed type 2 diabetes, higher ALP and lower creatinine were independently associated with increased PC risk before and after diabetes diagnosis, while haptoglobin showed a modest positive association. As these biomarkers are routine laboratory panels, their potential to support risk stratification in primary care requires further evaluation within established risk-prediction frameworks.


  • Open Access

    Machine-learning approach to atrial fibrillation prediction among individuals without prior cardiovascular diseases

    by Mozhu Ding, Shunsuke Murata, Javier Louro, Niklas Hammar, Karin Modig

    Background: There is a lack of atrial fibrillation (AF) prediction models tailored for individuals without prior cardiovascular diseases (CVDs) to facilitate early intervention. This study aimed to develop and validate an AF prediction model using machine-learning methods based on routine biomarkers in middle-aged individuals without overt CVD. Methods: Data were derived from 122 822 individuals in the Swedish AMORIS (Apolipoprotein-Mortality Risk) cohort who were aged 40–65 years and without CVD diagnosis at baseline (1985–96) and followed for 20 years for incident AF. The sample was split into training and validation data sets. Random forest was used to identify AF predictors from 16 routine biomarkers covering lipids, liver/kidney markers, glucose control and inflammation. Results: 10 356 (8.4%) incident AF diagnosis occurred over a mean of 18.1 years (SD 4.4). Model performance increased sharply when adding the first seven predictors and plateaued when adding additional ones. Therefore, a final AF prediction model was established based on seven predictors: age, albumin, uric acid, triglycerides, glucose, alkaline phosphatase and sex. C-statistics of the final model were 0.82 (95% CI: 0.81 to 0.82) in the training and 0.71 (0.70 to 0.72) in the validation data set in predicting 20-year AF. The model was well-calibrated in the full sample and age and sex subgroups. Conclusions: A new AF prediction model was established using seven biomarkers from a population without pre-existing CVDs, thus complementing currently available AF prediction models. These markers are readily accessible in primary and specialist care and demonstrate acceptable performance in predicting short- and long-term AF risk.


  • Open Access

    Dysglycaemia and incident aortic stenosis: a cohort study

    by Viktor Lind, Pia Lundman, Leif Friberg, Mats Talbäck, Niklas Hammar, Göran Walldius, Mozhu Ding, Anna Norhammar

    Background: Aortic stenosis is a degenerative condition with high mortality in its severe stages and no preventive treatment. While diabetes is a known risk factor, the role of elevated glucose levels below the diabetic threshold in the development of aortic stenosis remains unclear. This study investigated the association between dysglycaemia, including impaired fasting glucose, and the incidence of aortic stenosis.Methods: This study included 324 449 participants from the Swedish Apolipoprotein Mortality Risk cohort (1985–1996) who were free of aortic valve disease at baseline and had fasting glucose and lipid levels recorded. Participants were followed for incident aortic stenosis through the National Patient and Cause of Death Registers until 31 December 2020. Fasting glucose was categorised into low (<3.9 mmol/L), normal (3.9–6.0 mmol/L), impaired fasting glucose (6.1–6.9 mmol/L), high glucose (≥7.0 mmol/L) and diabetes. HRs were calculated using Cox proportional hazards models, with adjustments for age, sex, lipids, socioeconomic status, hypertension and kidney disease.Results: Over a mean follow-up of 25.9 years, 8523 participants developed aortic stenosis. Compared with normal glucose levels, adjusted HRs were 0.96 (95% CI 0.82 to 1.13) for low glucose, 1.36 (95% CI 1.24 to 1.50) for impaired fasting glucose, 1.79 (95% CI 1.60 to 1.99) for high glucose and 2.21 (95% CI 1.80 to 2.73) for diabetes. Spline analysis indicated a continuous increase in risk with rising glucose levels, even below the impaired fasting glucose threshold.Conclusions: Dysglycaemia, including glucose levels below the diabetic range, is associated with a higher risk of aortic stenosis.


  • Open Access

    Elevated Uric Acid Is Associated With New‐Onset Atrial Fibrillation: Results From the Swedish AMORIS Cohort

    by Mozhu Ding, Ngoc Nguyen Viet, Bruna Gigante, Viktor Lind, Niklas Hammar, Karin Modig

    Background: The role of uric acid is gaining increasing importance in the evaluation of cardiovascular disease, but its relationship with atrial fibrillation (AF) is unclear. This study aims to investigate the association between uric acid levels and risk of new‐onset AF. Methods and Results: A total of 339 604 individuals 30 to 60 years of age and free from cardiovascular disease at baseline (1985–1996) in the Swedish AMORIS (Apolipoprotein‐Mortality Risk) cohort were followed until December 31, 2019 for incident AF. Cox regression models were used to examine the association between uric acid and AF, adjusting for potential confounders and stratifying by incident cardiovascular disease. Over a mean follow‐up of 25.9 years, 46 516 incident AF cases occurred. Compared with the lowest uric acid quartile, each of the upper 3 quartiles were associated with an increased risk of AF in a dose–response manner. Adjusted hazard ratios were 1.09 (95% CI, 1.06–1.12) for second quartile, 1.19 (95% CI, 1.16–1.23) for third quartile, and 1.45 (95% CI, 1.41–1.49) for fourth quartile. The association was similar among individuals with and without incident hypertension, diabetes, heart failure, or coronary heart disease. The dose–response pattern was further supported in a subsample of individuals with repeated measurements of uric acid. Conclusions: Elevated uric acid was associated with an increased risk of AF, not only among people with cardiovascular disease and cardiovascular risk factors but also among those without. Future investigations are needed to examine whether lowering uric acid is relevant for AF prevention.


  • Open Access

    Carbohydrate, Lipid, and Apolipoprotein Biomarkers in Blood and Risk of Thyroid Cancer: Findings from the AMORIS Cohort

    by Xue Xiao, Yi Huang, Fetemeh Sadeghi, Maria Feychting, Niklas Hammar, Fang Fang, Zhe Zhang, Qianwei Liu

    Background: Previous studies have examined the link between blood metabolic biomarkers and risk of thyroid cancer, with inconclusive results. We performed a cohort study based on the Swedish Apolipoprotein-Related Mortality Risk (AMORIS) Cohort, including 561,388 individuals undergoing health examinations during 1985–1996 with a follow-up of >30 years. Methods: Newly diagnosed cases of thyroid cancer were identified from the Swedish Cancer Register. We assessed the associations of nine blood biomarkers of carbohydrate, lipid, and apolipoprotein metabolism measured at the time of health examinations with the subsequent risk of thyroid cancer and demonstrated the temporal trend of these biomarkers during the 30 years before diagnosis of thyroid cancer. Results: After multivariable adjustment, there was a lower risk of thyroid cancer, per standard deviation increase in total cholesterol (TC; HR 0.91; 95%CI 0.82–0.99) and HDL-C (HR 0.86; 95%CI 0.75–0.99). During the 20 to 30 years before diagnosis, patients with thyroid cancer, as a group, demonstrated constantly lower levels of TC and HDL-C, compared to controls. Further, patients with thyroid cancer demonstrated declining levels of these biomarkers during the ten years before diagnosis, whereas controls demonstrated stable or increasing levels. Conclusions: Taken together, we found blood levels of TC and HDL-C to be associated with the risk of thyroid cancer and that there was a declining level of metabolic biomarkers during the 10 years before diagnosis of thyroid cancer.


  • Open Access

    Long-term risk of a major cardiovascular event by apoB, apoA-1, and the apoB/apoA-1 ratio—Experience from the Swedish AMORIS cohort: A cohort study

    by Göran Walldius, Ulf de Faire, Lars Alfredsson, Karin Leander, Peter Westerholm, Håkan Malmström, Torbjörn Ivert, Niklas Hammar

    Background: Elevated apolipoprotein B (apoB) and elevated apoB/apoA-1 ratio increase the risk of myocardial infarction (MI) and stroke, whereas high apoA-1 is protective. We study how these apolipoproteins are associated with major adverse cardiovascular events (MACEs), whether apoA-1 contributes to this association, and whether abnormal values occur decades before such events develop. Methods and findings: In the Swedish AMORIS (Apolipoprotein-related MOrtality RISk) cohort study, 137,100 men and women aged 25–84 years were followed an average 17.8 years. ApoB, apoA-1, and the apoB/apoA-1 ratio were analysed in relation to MACEs (non-fatal MI, stroke, and cardiovascular [CV] mortality), yielding 22,473 events. Hazard ratios (HRs) were estimated using Cox regression. Kaplan–Meier estimates were used to investigate the relationship of MACEs with increasing quintiles of the apoB/apoA-1 ratio in all age groups for both sexes. In nested case–control analyses, cases were randomly matched to age- and sex-matched controls, yielding population trajectories for apolipoproteins. Increased level of apoB and increased apoB/apoA-1 ratio were associated with risk of MACE and all clinical sub-components in both men and women across all ages (10th versus first decile in both sexes combined: HR 1.7 for MACE and 2.7 for non-fatal MI). Decreased values of apoA-1 potentiated the impact of apoB at all levels of apoB (on average across apoB range: 40% increase in HR for MACE and 72% increase in HR for non-fatal MI), indicating that the apoB/apoA-1 ratio covers a broader range of persons with dyslipidaemia at risk than apoB alone. In both men and women, MACEs occurred earlier on average for each increasing quintile of the apoB/apoA-1 ratio. Individuals with the highest levels of apoB/apoA-1 ratio experienced CV events on average several years earlier than those with lower ratios. Higher apoB/apoA-1 ratio in cases of MACE versus controls was seen already about 20 years before the event. A limitation of this study was that adjustment for tobacco smoking and hypertension was only possible in a small validation study. Conclusions: An imbalance between apoB and apoA-1 resulting in an increased apoB/apoA-1 ratio is strongly associated with the outcome MACE and its sub-components, in both men and women of all ages. An increased apoB/apoA-1 ratio already 2 decades before events calls for early recognition and primary prevention. Simple evidence-based cut values should be considered in future cardiovascular guidelines.


  • Open Access

    Impaired fasting glucose: a risk factor for atrial fibrillation and heart failure

    by Viktor Lind, Niklas Hammar, Pia Lundman, Leif Friberg, Mats Talbäck, Göran Walldius, Anna Norhammar

    Background: Dysglycaemia is associated with overall cardiovascular disease even at prediabetes levels. The aim of this study was to explore the association between glucose levels and future risk of developing atrial fibrillation and heart failure, respectively. Methods: In this prospective cohort study subjects from the Swedish AMORIS-cohort with fasting glucose from health examinations 1985–1996 without previous cardiovascular disease (N = 294,057) were followed to 31 December 2011 for incident atrial fibrillation or heart failure. Cox proportional hazard models with attained age as timescale and adjustments for sex, cholesterol, triglycerides, and socioeconomic status were used to estimate hazard ratios by glucose categorized groups (normal glucose 3.9–6.0 mmol/L, impaired fasting glucose; 6.1–6.9 mmol/L, undiagnosed diabetes ≥ 7.0 mmol/L, and diagnosed diabetes). Results: During a mean follow-up time of 19.1 years 28,233 individuals developed atrial fibrillation and 25,604 developed heart failure. The HR for atrial fibrillation was 1.19 (95% confidence interval 1.13–1.26) for impaired fasting glucose, 1.23 (1.15–1.32) for undiagnosed diabetes and 1.30 (1.21–1.41) for diagnosed diabetes. Corresponding figures for heart failure were; 1.40 (1.33–1.48), 2.11 (1.99–2.23), 2.22 (2.08–2.36) respectively. In a subset with BMI data (19%), these associations were attenuated and for atrial fibrillation only remained statistically significant among subjects with diagnosed diabetes (HR 1.25; 1.02–1.53). Conclusions: Fasting glucose at prediabetes levels is associated with development of atrial fibrillation and heart failure. To some extent increased BMI may drive this association.


  • Open Access

    Serum Total Bilirubin and Risk of Cancer: A Swedish Cohort Study and Meta-Analysis

    by Maria J. Monroy-Iglesias, Charlotte Moss, Kerri Beckmann, Niklas Hammar, Goran Walldius, Cecilia Bosco, Mieke Van Hemelrijck, Aida Santaolalla

    Bilirubin has strong antioxidant properties that have been hypothesized to be preventive against the development of cancer. Thus, we aimed to investigate the association between serum total bilirubin (STB) and risk of overall and site-specific cancers in the large Swedish Apolipoprotein Mortality Risk (AMORIS) cohort. We also performed a systematic review and meta-analysis for specific cancer types (colorectal, breast and lung). We found no association between high levels of STB and risk of overall cancer. Regarding site-specific cancer, there was an inverse association between increased STB and lung cancer (Hazard Ratio (HR) for the 4th quartile (Q4) vs. Q1: 0.50; 95%CI: 0.44–0.59) and gynecological cancer (HR for Q4 vs. Q1: 0.86; 95%CI: 0.76–0.99). A positive association was found with melanoma (HR for Q4 vs. Q1: 1.25; 95%CI: 1.06–1.47) and breast cancer (HR for Q4 vs. Q1: 1.13; 95%CI: 1.01–1.25) risk. The meta-analysis showed an inverse association between high levels of STB and risk of lung cancer (Relative risk (RR): 0.69; 95%CI: 0.55–0.86). No associations were seen for colorectal and breast cancer risk. Further studies are required to establish if bilirubin can be used as a biomarker for risk assessment and/or as a novel therapeutic target.